HLB Life Science to acquire 100% of AIM for KRW 97.9bn
- Deal value
- $68m
- Stake
- 100%
- Implied 100%
- $68m
- Revenue
- $115m
- Op. income
- $29m
- Multiples
- EQV/EBIT 2.3xPSR 0.6x
Deal value ÷ stake (structure unconfirmed)
2021 별도 · DART-verified
2021 별도 · DART-verified
On implied equity value
DART 20220503000057
- Target
- AIM · IVD medical device consumables
- Buyer
- HLB Life Science · SI
- Seller
- AIM's largest shareholders
- Structure
- —
- Announced
- May 31, 2022
- Closed
- —
- Stage
- Signed
Target
AIM, founded in 2011, manufactures in-vitro diagnostic consumables such as specimen collectors and blood-collection devices through its own mold, injection and assembly processes, selling domestically and abroad; key customers include Abbott Diagnostics Korea and SD Biosensor.
Deal rationale
HLB Life Science director Kim Dae-yong said the company had recognized its market value relied only on future expectations, and that the deal secures a stable cash cow and strengthens the business structure. CEO Han Yong-hae said the year would mark its leap to a comprehensive new-drug and bio company. AIM's major shareholders take KRW 45bn of the price in convertible bonds and remain in management.
| Revenue | $115m |
| Operating income | $29m |
| EBITDA | — |
| Net income | — |
2021 별도 · DART-verified · 20220503000057
Press coverage
- 머니투데이 (2022-05-31): “HLB생명과학, 체외진단 의료기기 기업 에임 980억에 인수”
This is a data entry summarising filings and press reports. Please check the original sources for the figures.